

On July 13, 2012, DCH announced several Georgia Medicaid redesign initiatives. One of these initiatives was developing a common Preferred Drug List (PDL) for certain therapeutic classes across Fee-for-Service (FFS) and the Care Management Organizations (CMOs). The FAQs below may be helpful to your questions.

Q -- Does this mean there will be one Medicaid PDL across FFS and all three CMOs?

A -- No. DCH and the CMOs are working to develop commonality in certain therapeutic classes of drugs.

Q -- Will the CMOs be mandated to follow the FFS PDL?

A -- No. This is a collaborative initiative.

Q -- Which therapeutic classes of drugs will be included in this program?

A -- There is no preset listing of included or excluded therapeutic classes at this time. DCH and the CMOs will begin with classes where we have the most commonality and work from there.

Q -- Will this change the role of the DCH Drug Utilization Review (DUR) Board?

A -- No. The DUR Board role does not change. The DUR Board is advisory in nature to the department.

Q -- Will the CMOs have a voice in the DUR Board?

A -- Yes. A physician and pharmacist representative from each plan will be offered a voting role on the DUR Board.

Q -- Why is DCH undertaking this initiative?

A -- There are three (3) primary reasons. First, this will result in greater continuity of care as members move from FFS to a CMO, CMO to FFS, or CMO to CMO. This will decrease the situations where a patient established on a medication may have to switch to a new medication due to PDL placement of the drug. Second, this will result in administrative simplification for prescribers and pharmacies who care for our members. Third, this opens the door for DCH to pursue supplemental rebates (pending CMS approval) for CMO adjudicated pharmacy claims.

Q -- When will DCH begin contracting for supplemental rebates?

A -- Manufacturers will be notified when opportunities are available for submitting supplemental rebate offers that include CMO-adjudicated pharmacy claims. DCH does not anticipate that offers will be accepted until 2014.

Q -- As a manufacturer, can I submit a bid that includes the CMO lives for the bid cycle that begins in October, 2012?

A -- DCH is not accepting supplemental rebate bids for CMO claims for the bid cycle that opened in October 2012. **Manufacturers will be notified when opportunities are available for submitting supplemental rebate offers that include CMO-adjudicated pharmacy claims.** DCH does not anticipate that offers will be accepted until 2014.

Q -- How can I keep informed about the progress of this initiative?

A -- Updates regarding this and other GA Medicaid Pharmacy items can be found at <http://dch.georgia.gov/pharmacy> .